Fractyl Health (GUTS) reported a third-quarter loss of $1.39 per share, beating the consensus estimate of a $1.59 loss by 12.6%. Earnings improved 66.9% year over year, and the pre-revenue company again reported no revenue. The beat, however, is close to irrelevant to the investment case. The quarter was defined by a trade-off: Revita's REMAIN-1 pivotal cohort met its six-month co-primary endpoint, and the company then cut itself nearly in half to reach the next milestones. Clinical de-risking and financial fragility arrived together, and that is the central tension.

The quality of the beat deserves scrutiny. On a GAAP basis, the net loss narrowed to $14.2 million, or $1.07 per share after the October 1-for-12 reverse split, from $45.6 million a year earlier. Most of that improvement came from accounting, not operations. A $25.7 million favorable swing in the fair value of warrant liabilities did much of the work, including a $4.5 million non-cash gain this quarter. Operating improvement was real but modest. Total operating expenses fell to $18.6 million from $22.7 million as R&D dropped to $12.5 million, down from $13.8 million in Q2 and $15.6 million in Q1. SG&A rose to $6.2 million on higher personnel and stock compensation costs. Adjusted EBITDA was negative $16.0 million, versus negative $20.8 million a year ago, which means cash burn is still running near $16 million a quarter.

That burn rate collides with the balance sheet:

• **Cash:** down to $31.5 million, from $47.1 million in Q2 and $81.5 million at year-end.
• **Equity:** stockholders' equity has flipped to a $13.2 million deficit.
• **Debt:** long-term notes payable stand at $29.2 million.
• **Covenant:** the runway guidance is explicitly subject to a minimum liquidity covenant.

Management's response was decisive but painful. It is cutting roughly 45% of the workforce at about $2 million in severance, and it is discontinuing internal Rejuva development, a program that the Q2 call had slated for first patient dosing in the second half of 2026. Co-founder and President Jay Caplan has also retired. The payoff is a runway extended into Q2 2027, from early 2027 on the prior three calls, and quarterly cash spending guided down about 50% to roughly $8 million by the end of Q2 2027. Management now openly acknowledges that additional capital will be needed to bring Revita to market.

The clinical result is genuinely positive, but bears have legitimate ammunition:

• **The headline:** Revita patients retained about 80% of their GLP-1-induced weight loss versus 67% for sham (p=0.0023). There were no device- or procedure-related serious adverse events, and the separation between arms widened over time.
• **The missing figure:** management did not lead with a sham-adjusted headline effect.
• **Post hoc framing:** the most compelling figures come from post hoc ablation-length analyses, such as 53% less regain than sham at 20 cm or more.
• **A shifting bar:** the call analysis shows the success bar drifting lower. The Q4 FY25 call cited a roughly 70% regain reduction in an optimized subgroup. The Q1 call framed a roughly 50% reduction as a strong result. The Q3 call framed success as about half of sham regain, and only at full ablation length.
• **Confounders:** sham patients were roughly three times more likely to restart anti-obesity medication, which complicates interpretation. One Revita patient experienced GI hemorrhage events deemed possibly related, which could factor into FDA classification.
• **A stretched filing:** the De Novo submission now begins in late Q4 2026, but the full package will be completed only after 12-month data arrive in Q1 2027.

The forward catalysts are tangible:

• **Reimbursement coding:** a dedicated Category III CPT code takes effect January 1, 2027. That is earlier than the summer 2027 timing discussed previously, though the release (1122T) and the call (0122T) cite different code numbers.
• **Medicare coverage:** a CMS decision on a RAPID on-ramp is expected in early January.
• **Second co-primary endpoint:** the 12-month readout must clear a greater-than-50% performance goal. The call cited a post hoc responder rate above 97%.
• **Commercial timeline:** management laid out an explicit path for the first time, with potential authorization in late 2027 and launch in early 2028.

The market has treated the story harshly. Shares trade at $0.88, down 88.5% since opening at $7.68 after the August report. The stock is 87.5% below its $7.04 200-day moving average and about 90.9% below its August 21 inter-earnings high of $9.72. It set a 52-week low of $0.80 on November 11, the day before this report. Management's tone turned defensive, and a shareholder question asked how the company would restore credibility. Investor sentiment nonetheless improved sharply ahead of the release, rising from -0.91 to -0.08. That is still slightly negative, but far less hostile. The Earnings Whispers trend signals remain mostly negative, with price, sequential growth, and AVWAP readings all weak, while momentum has turned positive.

The bottom line is that Fractyl delivered the pivotal win it needed and bought itself time, but the runway reaches only to the next binary events. The EPS beat says little. What matters is whether the 12-month data, the De Novo filing, and the CMS decision can rebuild confidence before the company must raise capital from a deeply depressed share price.